A2A Pharmaceuticals
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
180 Varick St, New York City, New York, ...Website
www.a2apharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About A2A Pharmaceuticals
A2A Pharmaceuticals is a clinical stage oncology company focused on leveraging artificial intelligence and proprietary computational systems to develop novel drug alternatives for life-threatening diseases, including cancer and muscular dystrophy. Their lead asset, AO-252, is currently in Phase 1 clinical trials targeting ovarian, triple negative, and endometrial cancers, showing promising tumor reduction results. The company aims to expand its research into additional cancer types and has established partnerships with larger pharmaceutical companies for collaborative projects. A2A Pharmaceuticals is dedicated to advancing drug design and discovery through innovative technology and strategic collaborations.Explore more
A2A Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is A2A Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
A2A Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at A2A Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if A2A Pharmaceuticals had a recent Job posting/layoffs
Check out if A2A Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on A2A Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when A2A Pharmaceuticals launches new products
Check if A2A Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once A2A Pharmaceuticals has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to A2A Pharmaceuticals
Compare insights from companies similar to A2A Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
A2A Pharmaceuticals
<$5M
11-50
Private
-
2016
EP
Edward PainterFounder & Chairman & Chief Operating Officer
Company Profile Activity
Activity Insights
A2A Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
A2A Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about A2A Pharmaceuticals.
A2A Pharmaceuticals Tech Stack
A closer look at the technologies used by A2A Pharmaceuticals
A2A Pharmaceuticals News & Media
A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery
NEW YORK--(BUSINESS WIRE)--A2A Pharmaceuticals Inc. (A2A) announced an agreement to design and co-develop oncology drug candidates with Daewoong Pharmaceutical Co., Ltd. (Daewoong), a major pharmaceutical company in South Korea, using its proprietary AI-enabled drug discovery platform SCULPT™. The companies will collaborate on up to three oncology drug targets to accelerate Daewoong’s efforts to develop innovative oncology treatments through open collaboration. Under this collaboration, A2A wilA2A Pharmaceuticals Appoints New Advisors
NEW YORK--(BUSINESS WIRE)--A2A Pharmaceuticals Inc. (A2A), a biotechnology company committed to the advancement of innovative scientific research and new therapeutic agents, today announced the formation of its advisory board. Dr. Siddhartha Mukherjee is a pioneering physician, oncologist, and Pulitzer Prize winning author of numerous books which have redefined our understanding of human health, medicine and science such as The Emperor of All Maladies: A Biography of Cancer among others. He wilA2A Pharmaceuticals Appoints Dr. Sotirios Stergiopoulos Chief Executive Officer
NEW YORK, July 2, 2019 /PRNewswire/ -- A2A Pharmaceuticals Inc. (A2A), a biotechnology company committed to the advancement of innovative scientific research and new therapeutic agents, today announced the appointment of Dr. Sotirios G. Stergiopoulos as President and Chief Executive...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding A2A Pharmaceuticals
Sign Up For FreeTo access detailed company insights
A2A Pharmaceuticals is a clinical stage oncology company focused on leveraging artificial intelligence and proprietary computational systems to develop novel drug alternatives for life-threatening diseases, including cancer and muscular dystrophy. Their lead asset, AO-252, is currently in Phase 1 clinical trials targeting ovarian, triple negative,... Read More
